In a report published Thursday, Morgan Stanley analyst David R. Lewis reiterated an Overweight rating and $73.00 price target on Medtronic MDT.
In the report, Morgan Stanley “In the wake of new tax rules, investors have questioned whether a different deal structure could preserve accretion. Our analysis shows ways for MDT to create value by either decreasing stock consideration or – counterintuitively – offering even more equity to sidestep inversion limits entirely.”
Medtronic closed on Wednesday at $65.98.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in